Fang Kasie, Jung Minjoo, Sikorski Timothy, Licea-Perez Hermes
Biomarker and Bioanalytical Platforms, Precision Medicine, GSK 1250 S. Collegeville Rd, Collegeville, PA 19426, USA.
Biomarker and Bioanalytical Platforms, Precision Medicine, GSK 1250 S. Collegeville Rd, Collegeville, PA 19426, USA.
J Pharm Biomed Anal. 2025 Dec 15;266:117105. doi: 10.1016/j.jpba.2025.117105. Epub 2025 Aug 9.
Quantifying free payloads in biological matrices is essential for understanding Antibody-Drug Conjugates (ADC) off-target toxicity and safety. The bioanalysis of payloads is challenging due to the need to measure trace amount amidst abundant ADC, with minor ADC degradation potentially causing substantial payload overestimation. Successful assays require careful evaluation of payload structures and effective management of ADC-related interferences. This study identifies challenges for lactone-containing free payloads, mitigates their impact on bioanalysis, and develops a validated methodology for accurate measurement of these payloads in human serum. Lactone hydrolysis and its formation from carboxylate were evaluated at various pH values in buffer solutions and serum. The lactone was completely hydrolyzed at pH 8.5 (25°C) within 25 min; it took several hours at pH 7 and was stable at pH ≤ 6. Lactone regeneration from carboxylate was rapid at pH 3 (within 5 min) and slower at pH ≥ 4. In human serum, lactone hydrolysis was relatively fast (approximately 2 h at 37°C), suggesting the carboxylate form predominates in circulation. Stability experiments showed lactone hydrolysis in serum is reversible, eliminating the need for sample treatment at clinical sites. These insights were applied in the design of a method based on protein precipitation and solid-phase extraction to quantify total payload exposure (50-10,000 pg/mL) in serum in the presence of ADC (250 µg/mL). A double liquid-liquid extraction was employed to purify the ADC before use to prevent interferences in the selectivity and stability assessment. The assay was validated according to M10 guidance and used to support clinical studies.
定量生物基质中的游离有效载荷对于理解抗体药物偶联物(ADC)的脱靶毒性和安全性至关重要。由于需要在大量ADC中测量痕量物质,有效载荷的生物分析具有挑战性,ADC的轻微降解可能会导致有效载荷的大量高估。成功的检测需要仔细评估有效载荷结构并有效管理与ADC相关的干扰。本研究确定了含内酯游离有效载荷的挑战,减轻了它们对生物分析的影响,并开发了一种经过验证的方法,用于准确测量人血清中的这些有效载荷。在缓冲溶液和血清中的不同pH值下评估了内酯水解及其由羧酸盐形成的过程。内酯在pH 8.5(25°C)下25分钟内完全水解;在pH 7下需要数小时,在pH≤6时稳定。羧酸盐内酯再生在pH 3时迅速(5分钟内),在pH≥4时较慢。在人血清中,内酯水解相对较快(37°C下约2小时),表明羧酸盐形式在循环中占主导。稳定性实验表明血清中的内酯水解是可逆的,无需在临床现场进行样品处理。这些见解被应用于基于蛋白质沉淀和固相萃取的方法设计中,以在存在ADC(250μg/mL)的情况下定量血清中的总有效载荷暴露量(50 - 10,000 pg/mL)。在使用前采用双液液萃取纯化ADC,以防止干扰选择性和稳定性评估。该检测方法根据M10指南进行了验证,并用于支持临床研究。